BRAF and melanoma: As BRAF inhibitor PLX4032 induced resistance in melanoma patients bearing BRAFV 600E mutation, we also determined the efficacy of CUMA on A375-R, an in-house established BRAFV 600E mutant melanoma cell line with acquired resistance to PLX4032 (Feng et al., 2016).